Introduction
A best evidence topic was written according to a structured protocol. This protocol is fully described in ICVTS w1x.
Clinical scenario
Trans-catheter aortic valve implantation (TAVI) is a relatively new technique with growing clinical use. On a ward round, you notice that three patients who underwent TAVI the previous week for severe symptomatic calcific aortic stenosis (AS) have third degree atrioventricular block (AVB) on postoperative day (POD) 7. You are aware of the risk of this complication with conventional aortic valve replace- ment (AVR) but do not know the incidence or predictors of this complication in patients undergoing TAVI and decide to investigate.
Three-part question
In wpatients undergoing TAVIx what are the wincidence and predictorsx of wpostoperative permanent pacemaker implantationx?
Search strategy
All searches were limited to English language articles published after 2002 as TAVI was first performed in humans in 2002 w2x. MEDLINE was searched using the Ovid interface from 2002 to May 2010.
wsurgical procedures, minimally-invasiveyOR heart valve prosthesis implantationyOR aortic valveyOR aortic valve surgery.mpyOR heart catheterizationyOR transcutaneous Downloaded from https://academic.oup.com/icvts/article-abstract/12/2/243/742558 by guest on 26 January 2019 aortic valve implantation.mpyOR percutaneous aortic valve implantation.mpyOR trans-catheter aortic valve implantation.mpyOR TAVI.mpx AND wpacemaker, artificialyOR cardiac pacing, artificialyOR heart blockyOR permanent pacemaker.mpyOR permanent pacemaker implantation.mpx.
EMBASE was searched using the Ovid interface from 2002 to May 2010.
wminimally-invasive surgeryyOR heart valve replacementy OR heart valve surgeryyOR heart valve prosthesisyOR aorta valveyOR intervention cardiovascular procedureyOR catheterizationyOR aortic valve implantation.mpyOR transcutaneous aortic valve implantation.mpyOR percutaneous aortic valve implantation.mpyOR trans-catheter aortic valve implantation.mpyOR TAVI.mpx AND wpacemakeryOR artificial heart pacemakeryOR heart blockyOR permanent pacemaker.mpyOR permanent pacemaker implantation.mpx. Additionally, the CINAHL wCumulative Index to Nursing and Allied Health Literaturex database and the Cochrane Database for Systematic Reviews and Central Register of Controlled Trials were searched. All citations and abstracts were reviewed and the reference lists of articles found through these strategies were reviewed.
Search outcome
Due to the diverse terms used to describe TAVI, a broad search strategy was used and 3071 papers were found. On review 94 articles were relevant to TAVI and 14 were deemed to represent the best evidence. All 14 studies were multi-centre registries or single-centre retrospective case series containing G30 patients and reported incidence of postoperative permanent pacemaker (PPM) implantation. Five of these studies also assessed predictors of the need for PPM implantation. The author, journal, date and country of publication, study type, level of evidence, patient group, outcomes and results were tabulated (Table 1) w3-16x.
Discussion
All 14 studies were retrospective series or registries, inclusive of 2047 patients from Europe and North America. There is no randomised controlled data in this area.
Incidence
The mean short-term incidence of PPM implantation in patients undergoing TAVI assessed at hospital discharge (three studies), POD 14 (one study) or POD 30 (ten studies) is 14.2% (range 0-34%, median 9.7%). In comparison, the mean incidence of PPM implantation following AVR is 7.0% (range 3.0-11.8%, median 7.2%) w17-23x. The requirement for PPM implantation appears higher with the CoreValve prosthesis (five studies, mean 20.8%, range 9.3-30.0%) than with the Edwards-Sapien prosthesis (six studies, mean 5.4%, range 0-10.1%). Statistically significant in two studies that used both types of prosthesis (Ps0.018 and 0.008), this trend was observed in all three such studies w13, 14, 16x.
All eight studies that provided data on timing of PPM implantation describe the majority of indications arising in -5 days, with three studies seeing a majority within 24 hours w7, 14, 15x. Two studies investigated the need for ventricular pacing at one month and reported a mean proportion of ventricular pacing of 96.6"4.2% in all patients w12x, and 79.0"20.3% in the patients who were paced for )10% of the time (6y9 patients) w6x. Recovery of AVB therefore seems unlikely and early indications for PPM implantation should be utilised.
A significant increase in left bundle branch block (LBBB) postoperatively is reported in all seven studies that provide information regarding conduction disturbances. Of the studies providing data to 30 days, three describe persistent LBBB w 5, 6, 12x, while one reports no significant difference in incidence of LBBB between baseline and 30 days w9x. Persistent LBBB after AVR has been identified as a predictor of syncope, AVB and sudden cardiac death w24x. Only one study reported follow-up of patients with new LBBB following TAVI to six months and identified no further PPM requirement w3x. The importance of new onset persistent LBBB following TAVI is therefore unclear.
Predictors
Only two studies performed multivariate regression analysis to identify predictors of the need for PPM following TAVI w14, 16x. Independent factors identified as significant (P-0.05) were use of the CoreValve prosthesis and preexisting right bundle branch block (RBBB) w14x, and AVB at prosthesis implantation w16x. Additionally, Bleiziffer et al. identified use of the CoreValve prosthesis and borderline annulus size for prosthesis (a native annulus at the lower end of the recommended size range for a specific prosthesis) as having a considerable effect on the need for PPM implantation following TAVI. Although both factors were non-significant (Ps0.09 and 0.063, respectively), the confidence interval for the odds ratios for these factors included values as high as 17.6 and 5.9, respectively w16x.
The mechanism of conduction tissue injury during TAVI is speculated to be mechanical injury due to the prosthesis and the exclusion of the native calcified valve. Jilaihawi et al. hypothesise that factors such as the longer stent frame, self-expanding nature, or ovoid shape of the CoreValve prosthesis, in contrast to the Edwards-Sapien prosthesis, may induce greater compression of structures surrounding the aortic annulus w6x.
Clinical bottom line
We conclude that the current best available evidence suggests that the mean incidence of PPM implantation following TAVI is 14.2% (range 0-34%, median 9.7%), although this appears higher with the CoreValve prosthesis (five studies, mean 20.8%, range 9.3-30.0%) than with the Edwards-Sapien prosthesis (six studies, mean 5.4%, range 0-10.1%). The mean incidences of PPM implantation overall and when using the CoreValve prosthesis are higher than the mean incidence of 7.0% (range 3-11.8%, median 7.2%) following conventional AVR and may be explained by distinct differences between the patient groups involved and the procedure performed. Indications for PPM implantation appear to occur early in the postoperative period following TAVI and there is little evidence of recovery following AVB. New onset persistent LBBB is common following TAVI but the significance and follow-up required is unclear. M.G.D. Bates et al. / Interactive CardioVascular and Thoracic Surgery 12 (2011) PPM, permanent pacemaker; AVB, atrioventricular block; TAVI, trans-catheter aortic valve implantation; RBBB, right bundle branch block; AS, aortic stenosis; LBBB, left bundle branch block; OR, odds ratio; LVOT, left ventricular outflow tract; LAD, left axis deviation; IVSd, interventricular septum dimension in diastole; NCC, non-coronary cusp of the aortic valve; TOE, trans-oesophageal echocardiogram; LAHB, left anterior hemi-block; STS-PROM, society of thoracic surgeonspredicted risk of mortality; EOA, effective orifice area; CI, confidence interval; CHF, congestive heart failure; AVA, aortic valve area; ACC/AHA, American College of Cardiology/American Heart Association; ESC, European Society of Cardiology; ECG, electrocardiograph; SND, sinus node dysfuction.
Independent predictors of PPM requirement following TAVI include use of the CoreValve prosthesis and evidence of conduction system dysfunction, either pre-existing RBBB or AVB at the time of TAVI. All patients should be made aware of the high risk of PPM implantation with TAVI.
